A simple prognostic system in patients with myelofibrosis undergoing allogeneic stem cell transplantation: A CIBMTR/EBMT analysis Journal Article
| Authors: | Tamari, R.; McLornan, D. P.; Ahn, K. W.; Estrada-Merly, N.; Hernández-Bolud, J. C.; Giralt, S.; Palmer, J.; Gale, R. P.; DeFilipp, Z.; Marks, D. I.; van der Poel, M.; Verdonck, L. F.; Battiwalla, M.; Diaz, M. A.; Gupta, V.; Ali, H.; Litzow, M. R.; Lazarus, H. M.; Gergis, U.; Bashey, A.; Liesveld, J.; Hashmi, S.; Pu, J. J.; Beitinjaneh, A.; Bredeson, C.; Rizzieri, D.; Savani, B. N.; Abid, M. B.; Ganguly, S.; Agrawal, V.; Bacher, V. U.; Wirk, B.; Jain, T.; Cutler, C.; Aljurf, M.; Kindwall-Keller, T.; Kharfan-Dabaja, M. A.; Hildebrandt, G. C.; Pawarode, A.; Solh, M. M.; Yared, J. A.; Grunwald, M. R.; Nathan, S.; Nishihori, T.; Seo, S.; Scott, B. L.; Nakamura, R.; Oran, B.; Czerw, T.; Yakoub-Agha, I.; Saber, W. |
| Article Title: | A simple prognostic system in patients with myelofibrosis undergoing allogeneic stem cell transplantation: A CIBMTR/EBMT analysis |
| Abstract: | To develop a prognostic model for patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT) for myelofibrosis (MF), we examined the data of 623 patients undergoing allo-HCT between 2000 and 2016 in the United States (the Center for International Blood and Marrow Transplant Research [CIBMTR] cohort). A Cox multivariable model was used to identify factors prognostic of mortality. A weighted score using these factors was assigned to patients who received transplantation in Europe (the European Bone Marrow Transplant [EBMT] cohort; n = 623). Patient age >50 years (hazard ratio [HR], 1.39; 95% confidence interval [CI], 0.98-1.96), and HLA-matched unrelated donor (HR, 1.29; 95% CI, 0.98-1.7) were associated with an increased hazard of death and were assigned 1 point. Hemoglobin levels <100 g/L at time of transplantation (HR, 1.63; 95% CI, 1.2-2.19) and a mismatched unrelated donor (HR, 1.78; 95% CI, 1.25-2.52) were assigned 2 points. The 3-year overall survival (OS) in patients with a low (1-2 points), intermediate (3-4 points), and high score (5 points) were 69% (95% CI, 61-76), 51% (95% CI, 46-56.4), and 34% (95% CI, 21-49), respectively (P < .001). Increasing score was predictive of increased transplant-related mortality (TRM; P = .0017) but not of relapse (P = .12). The derived score was predictive of OS (P < .001) and TRM (P = .002) but not of relapse (P = .17) in the EBMT cohort as well. The proposed system was prognostic of survival in 2 large cohorts, CIBMTR and EBMT, and can easily be applied by clinicians consulting patients with MF about the transplantation outcomes. |
| Keywords: | survival; mutation; neoplasms; classification; therapy; jak2; ruxolitinib |
| Journal Title: | Blood Advances |
| Volume: | 7 |
| Issue: | 15 |
| ISSN: | 2473-9529 |
| Publisher: | American Society of Hematology |
| Date Published: | 2023-08-01 |
| Start Page: | 3993 |
| End Page: | 4002 |
| Language: | English |
| ACCESSION: | WOS:001055797900001 |
| DOI: | 10.1182/bloodadvances.2023009886 |
| PROVIDER: | wos |
| PMCID: | PMC10410129 |
| PUBMED: | 37134306 |
| Notes: | Article -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work